nsc 664704 has been researched along with Lymphoma in 1 studies
kenpaullone: inhibits CDK1/cyclin B; structure in first source
kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).
Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Montecillo-Aguado, M | 1 |
| Morales-MartÃnez, M | 1 |
| Huerta-Yepez, S | 1 |
| Vega, MI | 1 |
1 other study available for nsc 664704 and Lymphoma
| Article | Year |
|---|---|
KLF4 inhibition by Kenpaullone induces cytotoxicity and chemo sensitization in B-NHL cell lines via YY1 independent.
Topics: Apoptosis; B-Lymphocytes; Benzazepines; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Krupp | 2021 |